Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the efficacy and safety of three dose
levels of cobiprostone as compared to placebo in OA/RA patients treated with an NSAID for 20
months.
Phase:
Phase 2
Details
Lead Sponsor:
Sucampo Pharma Americas, LLC Sucampo Pharmaceuticals, Inc.